company background image
PPBT

Purple BiotechTASE:PPBT Stock Report

Market Cap

₪257.4m

7D

0.9%

1Y

-4.8%

Updated

24 Oct, 2021

Data

Company Financials
PPBT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PPBT Overview

Purple Biotech Ltd. is a clinical-stage company focused on advancing therapies to overcome tumor immune evasion and drug resistance to create treatments for cancer patients in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Purple Biotech
Historical stock prices
Current Share Price₪1.46
52 Week High₪1.21
52 Week Low₪2.48
Beta1.92
1 Month Change-3.76%
3 Month Change-6.53%
1 Year Change-4.82%
3 Year Change-71.24%
5 Year Change-89.05%
Change since IPO-99.21%

Recent News & Updates

May 28
Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Purple Biotech (TLV:PPBT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

PPBTIL PharmaceuticalsIL Market
7D0.9%-3.7%1.3%
1Y-4.8%-5.8%47.3%

Return vs Industry: PPBT matched the IL Pharmaceuticals industry which returned -4.6% over the past year.

Return vs Market: PPBT underperformed the IL Market which returned 47.9% over the past year.

Price Volatility

Is PPBT's price volatile compared to industry and market?
PPBT volatility
PPBT Beta1.92
Industry Beta1.44
Market Beta1

Stable Share Price: PPBT is not significantly more volatile than the rest of IL stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PPBT's weekly volatility has decreased from 11% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201013Isaac Israelhttps://purple-biotech.com

Purple Biotech Ltd. is a clinical-stage company focused on advancing therapies to overcome tumor immune evasion and drug resistance to create treatments for cancer patients in the United States. It operates through two segments, Oncology, and Pain and Hypertension. The company’s marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension.

Purple Biotech Fundamentals Summary

How do Purple Biotech's earnings and revenue compare to its market cap?
PPBT fundamental statistics
Market CapUS$80.24m
Earnings (TTM)-US$10.39m
Revenue (TTM)n/a

0x

P/S Ratio

-7.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PPBT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$10.40m
Earnings-US$10.39m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.059
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PPBT perform over the long term?

See historical performance and comparison

Valuation

Is Purple Biotech undervalued compared to its fair value and its price relative to the market?

1.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PPBT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PPBT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PPBT is unprofitable, so we can't compare its PE Ratio to the Asian Pharmaceuticals industry average.

PE vs Market: PPBT is unprofitable, so we can't compare its PE Ratio to the IL market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PPBT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PPBT is good value based on its PB Ratio (1.1x) compared to the IL Pharmaceuticals industry average (1.8x).


Future Growth

How is Purple Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Purple Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Purple Biotech performed over the past 5 years?

-17.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PPBT is currently unprofitable.

Growing Profit Margin: PPBT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PPBT is unprofitable, and losses have increased over the past 5 years at a rate of 17.9% per year.

Accelerating Growth: Unable to compare PPBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PPBT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.9%).


Return on Equity

High ROE: PPBT has a negative Return on Equity (-14.52%), as it is currently unprofitable.


Financial Health

How is Purple Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: PPBT's short term assets ($50.0M) exceed its short term liabilities ($3.5M).

Long Term Liabilities: PPBT's short term assets ($50.0M) exceed its long term liabilities ($870.0K).


Debt to Equity History and Analysis

Debt Level: PPBT is debt free.

Reducing Debt: PPBT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PPBT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PPBT has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 17.1% each year.


Dividend

What is Purple Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PPBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PPBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PPBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PPBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PPBT's dividend in 3 years as they are not forecast to pay a notable one for the IL market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Isaac Israel (43 yo)

9yrs

Tenure

US$1,128,745

Compensation

Mr. Isaac Israel has been the Chief Executive Officer of Purple Biotech Ltd. (formerly known as Kitov Pharma Ltd). (formerly, Kitov Pharmaceuticals Holdings LTD.) since October 2012.Prior to joining Kitov...


CEO Compensation Analysis

Compensation vs Market: Isaac's total compensation ($USD1.13M) is above average for companies of similar size in the IL market ($USD414.84K).

Compensation vs Earnings: Isaac's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PPBT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: PPBT's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.4%.


Top Shareholders

Company Information

Purple Biotech Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Purple Biotech Ltd.
  • Ticker: PPBT
  • Exchange: TASE
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₪257.367m
  • Shares outstanding: 176.16m
  • Website: https://purple-biotech.com

Number of Employees


Location

  • Purple Biotech Ltd.
  • 4 Oppenheimer Street
  • Science Park
  • Rehovot
  • 7670104
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/24 22:28
End of Day Share Price2021/10/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.